key: cord-0759709-6fy5ic8x
authors: Sim, Jackie; Lee, Tung Lin; Lim, Cynthia Ciwei
title: COVID-19 vaccination in anti-neutrophil cytoplasmic antibody-associated vasculitis: lessons from influenza vaccination?
date: 2022-02-25
journal: Clin Kidney J
DOI: 10.1093/ckj/sfac053
sha: ec784654a3d18a31bbbe3162dd1f3ee9f101b944
doc_id: 759709
cord_uid: 6fy5ic8x

nan

The emergence of de novo and relapsing anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) following coronavirus disease 2019 (COVID-19) vaccination [1] in the midst of an unprecedented rapid global vaccination drive against COVID-19 is reminiscent of that reported after influenza vaccination [2] . A recent pharmacoepidemiological study of drugassociated AAV reported in the World Health Organization pharmacovigilance database between 2006 and 2020 found that influenza vaccination was one of the 15 drugs with disproportionate reporting for AAV [2] . However, earlier studies had noted that among prevalent AAV, disease activity scores did not change significantly [4] [5] [6] [7] [8] . Conversely, influenza infection risk, morbidity and mortality are significantly amplified in autoimmune disease and immunosuppression [9] , thus lending support for influenza vaccination in prevalent AAV and other autoimmune conditions [3] .

Since COVID-19 vaccine trial safety data in AAV are lacking as most trials have excluded immunosuppressed patients, a future pharmacoepidemiological study that includes emerging data such as that reported by Fillon et al. [1] may provide insights into the role of COVID-19 vaccines in de novo and relapsing AAV. In the meantime, the benefit of vaccinations for preventable infections such as influenza and COVID-19 with elevated infection-related mortality in immunosuppression likely outweighs the possibility of a disease flare. Increased physician and patient awareness and surveillance postvaccination may be considered in patients with immune-mediated kidney disease, including AAV [10] .

De novo and relapsing necrotizing vasculitis after COVID-19 vaccination

A worldwide pharmacoepidemiological update of drug-associated ANCAassociated vasculitis at the time of targeted therapies

update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases

Wegener's granulomatosis patients show an adequate antibody response to influenza vaccination

Randomized trial investigating the safety and efficacy of influenza vaccination in patients with antineutrophil cytoplasmic antibody-associated vasculitis

Immunogenicity and safety of the 2009 non-adjuvanted influenza A/H1N1 vaccine in a large cohort of autoimmune rheumatic diseases

Influenza vaccination does not result in an increase in relapses in patients with ANCA-associated vasculitis

Antibody response to inactivated subunit influenza vaccine in patients with Wegener's granulomatosis

Incidence and prevalence of vaccine preventable infections in adult patients with autoimmune inflammatory rheumatic diseases (AIIRD): a systemic literature review informing the 2019 update of the EULAR recommendations for vaccination in adult patients with AIIRD

De novo and relapsing glomerular diseases after COVID-19 vaccination: what do we know so far?

This article has not been published previously in whole or part. All authors declare no potential conflict of interest.